DNLI News and Press, Denali Therapeutics Inc. From 01/21/21

F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value. The company has an exciting pipeline of early immuno-therapy clinical assets from F-star's recent pivot, 2 years ago, to internal drug development. ...

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Nancy...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

Biopharmaceutical company Denali Therapeutics ([[DNLI]] +7.5%) highlights pipeline updates and 2021 milestones ahead of the coveted annual J.P. Morgan Healthcare Conference lined up next week.Phase 1b study of LRRK2 inhibitor, DNL151 (BIIB122), collaborating with Biogen, in Parkinson’s...

Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II) to be held at WORLD Symposium on February 12th Following previously announced data on CSF GAG reduction with DNL310 and achievement of biomarker proof-of-...

Denali has a market cap of $10bn after Biogen's $1bn deal with it. Its assets are in the early stages. While 3 major biopharma companies have gambled on Denali, the stakes are too high right now. For further details see: Denali: A $10B Early Stage Biotech Targeting Parki...

A funny thing happened on the way to the Christmas holidays and the end of the final quarter of 2020. All of a sudden, out of the blue, shares of multiple unrelated stocks began to sell off. As the final hour of trading got under way Wednesday, shares of database software company Mong...

Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At Jefferies London Healthcare Conference - Slideshow

Often, the best investments are the ones most of the market isn't paying attention to. With all eyes focused on coronavirus stocks, it may be a good time for investors to look at the possibilities for progress on other diseases that have plagued us for a lot longer. Alzheimer's, for exa...